SHP611

Phase 2Small molecule

Takeda

SHP611 is one of 6 small molecule programs targeting Metachromatic Leukodystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metachromatic LeukodystrophyActive, not recruiting

Metachromatic Leukodystrophy (MLD)Completed

Metachromatic LeukodystrophyPhase 2

Active, not recruiting

Metachromatic Leukodystrophy (MLD)Phase 2

Completed

Competition

Competitive Landscape

8 competitors in Metachromatic Leukodystrophy

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Approved

—2

Cytoxan

BBaxter Healthcare Corporation

RG6026

Recombinant Human Arylsulfatase a

Takeda

Phase 2

2 5

SHP611

Takeda

Phase 2

1 6

Coumadin

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metachromatic Leukodystrophy (MLD)1 trial

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy

Completed· Takeda logo

Takeda·Phase 2·NCT03771898·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHP611. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHP611 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHP611. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

SHP611

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metachromatic Leukodystrophy (MLD)1 trial

References

Drug Info

Quick Facts

Related News